; or (C) entitled to benefits under part A of title XVIII or enrolled under part B of such title. (2) Maximum fair price The term maximum fair price means, with respect to a plan year during a price applicability period and with respect to a selected drug (as defined in section 1192(c)) with respect to such period, the price published pursuant to section 1195 in the Federal Register for such drug and year. (3) Average international market price defined (A) In general The terms average international market price and AIM price mean, with respect to a drug, the average price (which shall be the net average price, if practicable, and volume-weighted, if practicable) for any dosage form and strength of a unit (as defined in subparagraph (C)) for the drug for sales of such drug, as computed (as of the date of publication of such drug as a selected drug under section 1192(a)) in all countries described in clause (ii) of subparagraph (B) that are applicable countries (as described in clause (i) of such subparagraph) with respect to such drug. (B) Applicable countries (i) In general For purposes of subparagraph (A), a country described in clause (ii) is an applicable country described in this clause with respect to a drug if there is available an average price for any unit for the drug for sales of such drug in such country. (ii) Countries described For purposes of this paragraph, the following are countries described in this clause: (I) Australia. (II) Canada. (III) France. (IV) Germany. (V) Japan. (VI) The United Kingdom. (C) Unit The term unit means, with respect to a drug, the lowest identifiable quantity (such as a capsule or tablet, milligram of molecules, or grams) of the drug that is dispensed. 1192. Selection of negotiation-eligible drugs as selected drugs (a) In general Not later than the selected drug publication date with respect to an initial price applicability year, the Secretary shall select and publish in the Federal Register a list of— (1) at least 25 negotiation-eligible drugs described in subparagraphs